R. Rhomberg, R. K. Flamm, R. N. Jones, H. S. Sader; JMI Lab., N Liberty, IA. Deane, A. Simenauer, D. Sahm; Eurofins, Chantilly, VA. C2-126 Deane S. Sader, R. K. Flamm, R. N. Jones; JMI Lab., Inc., N Liberty, IA. C2-130

45 SUNDAY SCIENTIFIC SESSIONS Final Program ------------------------------------------------------------------------ 010 C2 Poster Session Multi-Center Surveillance Studies Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: C2-123 Ceftaroline Activity Tested against Pathogens Associated With Acute Bacterial Skin and Skin Structure Infections ABSS- SI Isolated From Latin American Medical Centers 2010

D. J. Biedenbach, H. S. Sader, R. K. Flamm, R. N. Jones; JMI Lab., Inc., N Liberty, IA.

C2-124 Antimicrobial Activity of Ceftaroline and Comparator Agents Tested against Contemporary 2010 Pathogens Associ- ated with Acute Bacterial Skin and Skin Structure Infections ABSSSI Isolated from the Asia-Pacific Region APAC and South Africa SAF

P. R. Rhomberg, R. K. Flamm, R. N. Jones, H. S. Sader; JMI Lab., N Liberty, IA.

C2-125 Comparative In Vitro Activity of Sitafloxacin SIT Relative to Other Fluoroquinolones against Clinically Important Bacteria Isolated in Asia and Europe

J. Deane, A. Simenauer, D. Sahm; Eurofins, Chantilly, VA. C2-126

In Vitro Activity of Ceftaroline against Staphylococcus aureus SA from Consecutive U.S. Nationwide Surveillance Program 2009 and 2011 G. Doern 1 , S. Richter 2 , K. Heilmann 1 , C. Dohrn 1 , F. Riahi 1 , D. Diekema 1 ; 1 Univ. of Iowa, Iowa City, IA, 2 Cleveland Clinic, Cleveland, OH. C2-127 Comparative In Vitro Activity of Ceftaroline, Daptomycin, Linezolid, and Vancomycin against 512 Bacteremic Methicillin- Resistant Staphylococcus aureus Isolated Over a Period of 9 Years 2004-2012 in Madrid, Spain E. Cercenado, B. Gama, C. Sánchez-Carrillo, M. Marín, M. Rodríguez- Créixe, E. Bouza; Hosp. Gen. Univ. Gregorio Marañón, Madrid, Spain. C2-128 A Five Year Comparison of Vancomycin VAN and Orita- vancin ORI In Vitro Activities against Staphylococci

J. Deane

1 , A. Simenauer 1 , G. Moeck 2 , F. F. Arhin 2 , D. Sahm 1 ; 1 Eurofins, Chantilly, VA, 2 The Med. Company, Parsippany, NJ. C2-129 Antimicrobial Susceptibility of S. aureus from USA Hospitals According to the Site of Infection: Data from the Ceftaroline AWARE Surveillance Program 2008-2011

H. S. Sader, R. K. Flamm, R. N. Jones; JMI Lab., Inc., N Liberty, IA. C2-130

Activity of Ceftaroline Tested against Staphylococcus Collected from a Nationwide Study in Spain, 2010 E. Cercenado, B. Gama, O. Cuevas, M. Marín, E. Bouza, Staphylococcus Study Group; Hosp. Gen. Univ. Gregorio Marañón, Madrid, Spain. C2-131 Ceftaroline and Comparator Agent Activity against Con- temporary 2010 Staphylococcus aureus Isolates from Asia-Pacific APAC Region and South Africa Hospitals

P. R. Rhomberg, R. K. Flamm, R. N. Jones, H. S. Sader; JMI Lab., Inc., N Liberty, IA.